Use of nonsteroidal Antiinflammatory drugs an update for clinicians - A scientific statement from the American Heart Association

被引:591
作者
Antman, Elliott M.
Bennett, Joel S.
Daugherty, Alan
Furberg, Curt
Roberts, Harold
Taubert, Kathryn A.
机构
关键词
AHA Scientific Statements; aspirin; inhibitors; drugs; antiinflammatory agents; nonsteroidal; coxibs; cyclooxygenase; 2;
D O I
10.1161/CIRCULATIONAHA.106.181424
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Current evidence indicates that selective COX-2 inhibitors have important adverse cardiovascular effects that include increased risk for myocardial infarction, stroke, heart failure, and hypertension. The risk for these adverse effects is likely greatest in patients with a prior history of or at high risk for cardiovascular disease. In these patients, use of COX-2 inhibitors for pain relief should be limited to patients for whom there are no appropriate alternatives, and then, only in the lowest dose and for the shortest duration necessary. More long-term data are needed to fully evaluate the extent to which these important adverse cardiovascular effects may be offset by other beneficial effects of these medications. More data are also needed on the cardiovascular safety of conventional NSAIDs. Until such data are available, the use of any COX inhibitor, including over-the-counter NSAIDs, for long periods of time should only be considered in consultation with a physician. The debate about the increased risk of cardiovascular events attributed to the selective COX-2 inhibitors and the nonselective NSAIDs is part of a broader national debate about drug safety. Optimal safety evaluation of drugs requires timely and complete submission of scientific data from the manufacturers, as well as increased funding and authority granted to the FDA by Congress. © 2007 American Heart Association, Inc.
引用
收藏
页码:1634 / 1642
页数:9
相关论文
共 47 条
  • [1] [Anonymous], FUT DRUG SAF PROM PR
  • [2] Cyclooxygenase inhibition and cardiovascular risk
    Antman, EM
    DeMets, D
    Loscalzo, J
    [J]. CIRCULATION, 2005, 112 (05) : 759 - 770
  • [3] Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis
    Bea, F
    Blessing, E
    Bennett, BJ
    Kuo, CC
    Campbell, LA
    Kreuzer, J
    Rosenfeld, ME
    [J]. CARDIOVASCULAR RESEARCH, 2003, 60 (01) : 198 - 204
  • [4] Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis
    Belton, OA
    Duffy, A
    Toomey, S
    Fitzgerald, DJ
    [J]. CIRCULATION, 2003, 108 (24) : 3017 - 3023
  • [5] The use of nonsteroidal anti-inflammatory drugs (NSAIDs) - A science advisory from the American Heart Association
    Bennett, JS
    Daugherty, A
    Herrington, D
    Greenland, P
    Roberts, H
    Taubert, KA
    [J]. CIRCULATION, 2005, 111 (13) : 1713 - 1716
  • [6] Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
    Bresalier, RS
    Sandler, RS
    Quan, H
    Bolognese, JA
    Oxenius, B
    Horgan, K
    Lines, C
    Riddell, R
    Morton, D
    Lanas, A
    Konstam, MA
    Baron, JA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) : 1092 - 1102
  • [7] ARTERIAL-WALLS GENERATE FROM PROSTAGLANDIN ENDOPEROXIDES A SUBSTANCE (PROSTAGLANDIN-X) WHICH RELAXES STRIPS OF MESENTERIC AND CELIAC ARTERIES AND INHIBITS PLATELET-AGGREGATION
    BUNTING, S
    GRYGLEWSKI, R
    MONCADA, S
    VANE, JR
    [J]. PROSTAGLANDINS & OTHER LIPID MEDIATORS, 1976, 12 (06) : 897 - 913
  • [8] Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice
    Burleigh, ME
    Babaev, VR
    Oates, JA
    Harris, RC
    Gautam, S
    Riendeau, D
    Marnett, LJ
    Morrow, JD
    Fazio, S
    Linton, MF
    [J]. CIRCULATION, 2002, 105 (15) : 1816 - 1823
  • [9] Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
    Cannon, Christopher P.
    Curtis, Sean P.
    FitzGerald, Garret A.
    Krum, Henry
    Kaur, Amarjot
    Bolognese, James A.
    Reicin, Alise S.
    Bombardier, Claire
    Weinblatt, Michael E.
    van der Heijde, Desiree
    Erdmann, Erland
    Laine, Loren
    [J]. LANCET, 2006, 368 (9549) : 1771 - 1781
  • [10] Clinical trial design and patient demographics of the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study program: Cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis
    Cannon, Christopher P.
    Curtis, Sean P.
    Bolognese, James A.
    Laine, Loren
    [J]. AMERICAN HEART JOURNAL, 2006, 152 (02) : 237 - 245